Daily Dose Equities - Wall Street Analysis for Biomedical Research

Daily Dose Newsroom Index

Top

Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter

Entries in rodman renshaw (3)

Friday

May182012

Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey

DDE Editor

Rodman & Renshaw has released a report in conjuction with Pharm3r about a data-mining project to crowd source opinions and in interest in new drugs on Twitter. Pharm3r is unique data-mining company that tags plain text in order to mine such disparate sources as chat boards, blogs, and Twitter feeds.

Analyst Michael King, Jr. writes,

"Our first foray into this novel approach to crowd-sourcing opinions and views on various topics begins with the recent 2012 American Academy of Neurology (AAN), which took place April 21-28 in New Orleans. While AAN deals with dozens of topics, Pharm3r gathered views on the 24 most common discussions. Relevant tweets were scanned for a predetermined list of topics between April 20th and 30th. Each topic is also accompanied by a sentiment score...

We view the combination of Twitter volume (number of tweets) and sentiment of those tweets as highly relevant data points in assessing interest in a drug within a period of time. The ability to view that interest compared to other relevant drugs at a time of high interest and tweeting provide an opportunity for potential insight into clinician, patient, and investor interest."

The results from the project include the following:

"Starting with multiple sclerosis (MS), the updated safety regulation in the US and EU spurred a significant volume of relatively negatively tweets for Gilenya (fingolimod), while Lemtrada (alemtuzumab) and BG-12 tweets generated relatively high sentiment...Turning to therapies for Amyotrophic Lateral Sclerosis (ALS), CK2017357 (‘357) from Cytokinetics (CYTK, Market Outperform) bested Biogen’s dexpramipexole in both volume and sentiment."

Rodman & Renshaw Annual Global Investment Conference September 9-11, 2012 in NYC

DDE Editor

Rodman & Renshaw will have its 14th annual healthcare conference from September 9-11, 2012 at the Waldorf Astoria in New York, NY.

The Annual Global Investment Conference has the following areas of interest:

Autoimmune Diseases
Cardiovascular Diseases
CNS Disorders
Drug Delivery
Gene Therapy
Infectious Diseases
Medical Devices
Molecular Diagnostics
Oncology
Orphan Diseases
Stem Cells
Vaccines

WHO SHOULD ATTEND:

Institutional Investors
Venture Capital Firms
Sophisticated Private Investors
Industry Executives
Business Development Executives
Private Equity Firms

CONFERENCE FORMAT:

Corporate Presentations
Investor One-on-One Meetings
Daily Networking Opportunities over Breakfast, Lunch and Cocktails

For more information, see www.rodmanandrenshaw.com.

Rodman & Renshaw 2012 Annual Global Investment Conference Dates are set

DDE Editor

The Rodman & Renshaw Annual Global Investment Conference will be held on September 9-11, 2012 at The Waldorf Astoria in New York. Registration for this upcoming conference is NOW OPEN on the website.

September 9-11, 2012 , New York, NY
Rodman & Renshaw 14th Annual Healthcare Conference

September 9-11, 2012 , New York, NY
Rodman & Renshaw Energy Track

September 9-11, 2012 , New York, NY
Rodman & Renshaw Technology Track

September 9-11, 2012 , New York, NY
Rodman & Renshaw Industrial Track

September 9-11, 2012 , New York, NY
Rodman & Renshaw Israel Track

Post a Comment →

tagged

rodman renshaw,

waldorf astoria |

Print Article

Email Article Posted on

Wednesday, February 29, 2012 at 8:00AM

Permalink in

Conferences

Copyright by Daily Dose Equities. All rights reserved. This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation that any of the securities mentioned herein are appropriate for any specific individual circumstances and does not guarantee that future results or performance will match those predicted to occur. Although every effort is made to ensure the accuracy and completeness of the information on this website by using reliable data sources such as SEC filings and press releases, no guarantees are made in this regard as it has not been reviewed or certified by an independent auditor and may also include the opinions and future projections of the author. The contributing authors on this website are not chartered financial analysts, registered investment advisors or broker/dealers, and do not provide individual investment advice. The information provided by the writers on this website is for informational purposes only and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The information appearing on this website, blog, and related publications has not been reviewed or endorsed by any of the companies mentioned and should not be regarded as offical corporate news, publications, or shareholder communications. Film Annex Capital Partners, LLC (FACP) is the owner of this website and they provide strategic advisory, social media, and marketing services to emerging-growth companies. A number of the companies displayed on this site may be current or previous clients of FACP. In most instances, FACP has received fees for services for the creation, preparation and distribution of materials featured on this site, which are paid for in cash and/or stock, by the featured company ("client"). More detailed disclosure regarding fees paid is available upon request. FACP is not a broker/dealer or registered investment advisor. Information contained throughout this site is not an offer to buy or sell securities. Information presented on this site is solely for informative purposes, and is not intended, nor should they be construed, as investment advice. The information provided including news, blogs, corporate profiles, and other material is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. The companies featured on this site are typically development-stage and investment in such securities is considered highly speculative and carries a high degree of risk. Complete loss of capital is a distinct possibility. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org. Opinions stated herein may be solely FACP or the indicated source's, and not necessarily those of the featured Company. Officers, directors, and employees of FACP and financial analysts mentioned, and/or members of their families, may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. 2010-12 Film Annex Capital Partners, LLC. All rights reserved.